ExodusPoint Capital Management’s Epizyme, Inc EPZM Stock Holding History

ExodusPoint Capital Management’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-98,107	Closed	-$113K	–	2737
2022 Q1	$113K	Sell	98,107 -261,365	-73%	-$426K	﹤0.01%	1992
2021 Q4	$899K	Buy	+359,472	New	+$1.41M	0.01%	1132
2021 Q3	–	Sell	-36,838	Closed	-$306K	–	2867
2021 Q2	$306K	Buy	36,838 +20,681	+128%	+$174K	﹤0.01%	1727
2021 Q1	$141K	Sell	16,157 -20,245	-56%	-$209K	﹤0.01%	1933
2020 Q4	$395K	Buy	36,402 +22,084	+154%	+$272K	﹤0.01%	1392
2020 Q3	$171K	Sell	14,318 -13,346	-48%	-$179K	﹤0.01%	1515
2020 Q2	$444K	Buy	+27,664	New	+$483K	0.01%	1137

Other funds holding EPZM

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ExodusPoint Capital Management's EPZM Position: Q2 2022 in Review

ExodusPoint Capital Management sold out of Epizyme, Inc (EPZM) in Q2 2022, closing a stake of 98,107 shares — an estimated $113K sold.

ExodusPoint Capital Management first reported a position in EPZM in Q2 2020 and held it in 7 quarters. The position peaked at $899K in Q4 2021. 93 funds tracked by Wall St. Rank hold EPZM as of Q2 2022.

ExodusPoint Capital Management reported no remaining Epizyme, Inc position as of Q2 2022 after selling out during the quarter.
ExodusPoint Capital Management sold 98,107 Epizyme, Inc shares in Q2 2022, an estimated $113K.
ExodusPoint Capital Management first reported a position in Epizyme, Inc in Q2 2020 and held it in 7 quarters.
ExodusPoint Capital Management's Epizyme, Inc position peaked at $899K in Q4 2021.
93 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2022.

Based on ExodusPoint Capital Management's 13F filing for Q2 2022, filed 22 Aug 2022.